#biopharmaceuticalcompany — Public Fediverse posts

Summit shares surge after-hours on $2 billion AstraZeneca equity deal

Investing.com — Summit Therapeutics PLC (NASDAQ:SMMT) shares surged 15% in extended trading on Monday after pharmaceutical giant AstraZeneca…
#EuropeSays #Britain #Europe #EU #AstraZeneca #AstraZenecaPLC #biopharmaceuticalcompany #bispecificantibody #equityinvestment #substantialcapital #SummitTherapeutics
https://www.europesays.com/britain/134209/

https://www.europesays.com/britain/134209/ Summit shares surge after-hours on $2 billion AstraZeneca equity deal #AstraZeneca #AstraZenecaPLC #BiopharmaceuticalCompany #BispecificAntibody #EquityInvestment #SubstantialCapital #SummitTherapeutics

Summit shares surge after-hours on $2 billion AstraZeneca equity deal

Investing.com — Summit Therapeutics PLC (NASDAQ:SMMT) shares surged 15% in extended trading on Monday after pharmaceutical giant AstraZeneca…
#EuropeSays #Britain #Europe #EU #AstraZeneca #AstraZenecaPLC #biopharmaceuticalcompany #bispecificantibody #equityinvestment #substantialcapital #SummitTherapeutics
https://www.europesays.com/britain/133349/

https://www.europesays.com/britain/133349/ Summit shares surge after-hours on $2 billion AstraZeneca equity deal #AstraZeneca #AstraZenecaPLC #BiopharmaceuticalCompany #BispecificAntibody #EquityInvestment #SubstantialCapital #SummitTherapeutics

ORYZON Receives European Medicines Agency Approval to Initiate the HOPE-2 Phase II Study of Vafidemstat for the Treatment of Phelan-McDermid Syndrome (PMS)

Oryzon Genomics, S.A. PMS…
#Europe #EU #aggression #autism #biopharmaceuticalcompany #borderlinepersonalitydisorder #European #EuropeanInterest #EuropeanMedicinesAgency #EuropeanUnion #geneticdisorder #neurodevelopmentaldisorder #PhaseIIstudy #Phelan-McDermidSyndrome #SyndromeAssociation #vafidemstat
https://www.europesays.com/europe/148076/

https://www.europesays.com/3270860/ Arcus Biosciences Announces New Employment Inducement Grants #ArcusBiosciences #BiopharmaceuticalCompany #business #CompensationCommitteeOfTheCompany’sBoardOfDirectors #Inc #InflammatoryDiseases #jobs #NYSEListedCompanyManual #TreatmentOfCancer

AstraZeneca Gains as Enhertu Clears England’s Value Gate

This article first appeared on GuruFocus. AstraZeneca (NYSE:AZN), the oncology and biopharmaceutical company, secured a major access win…
#EuropeSays #Britain #Europe #EU #AstraZeneca #biopharmaceuticalcompany #England #Enhertu #GuruFocus #reimbursement
https://www.europesays.com/britain/126349/

https://www.europesays.com/britain/126349/ AstraZeneca Gains as Enhertu Clears England’s Value Gate #AstraZeneca #BiopharmaceuticalCompany #England #Enhertu #GuruFocus #reimbursement

AstraZeneca Falls 1.3% Despite a 34% COPD Breakthrough

This article first appeared on GuruFocus. AstraZeneca (NYSE:AZN), the global oncology and biopharmaceutical company, fell approximately 1.3% to…
#EuropeSays #Britain #Europe #EU #AstraZeneca #biopharmaceuticalcompany #clinicaldata #COPDtreatment #GuruFocus #OBERONandTITANIA
https://www.europesays.com/britain/124095/

https://www.europesays.com/britain/124095/ AstraZeneca Falls 1.3% Despite a 34% COPD Breakthrough #AstraZeneca #BiopharmaceuticalCompany #ClinicalData #COPDTreatment #GuruFocus #OBERONAndTITANIA

https://www.europesays.com/ch/128445/ Why the Dow is being dragged down by a Swiss company’s bad news #Amgen #BiopharmaceuticalCompany #dow #Novartis #RivalCompany #Swiss #Switzerland

OKYO Pharma to Present at Ophthalmology Futures European Forum and iNovation Day at ESCRS 2026

OKYO Pharma LTD Company to engage with the global ophthalmology and investment community as it advances urcosimod through…
#Europe #EU #biopharmaceuticalcompany #clinicalpath #ESCRS #European #industryleaders #NASDAQ #OKYO #OKYOPharma #OKYOPharmaLimited #Ophthalmology
https://www.europesays.com/europe/134069/

https://www.europesays.com/britain/120166/ AstraZeneca Falls Today Even as Imfinzi Wins a Landmark Survival Test #Amgen #AstraZeneca #BiopharmaceuticalCompany #Imfinzi #SurvivalData

AstraZeneca Falls Today Even as Imfinzi Wins a Landmark Survival Test

This article first appeared on GuruFocus. AstraZeneca (NYSE:AZN), the oncology and biopharmaceutical company, reported a late-stage lung-cancer victory…
#EuropeSays #Britain #Europe #EU #AstraZeneca #Amgen #biopharmaceuticalcompany #Imfinzi #survivaldata
https://www.europesays.com/britain/120166/

NewAmsterdam Pharma Announces Upcoming Presentations at the European Society of Cardiology (ESC) Congress 2026

NewAmsterdam Pharma N.V. NAARDEN, The Netherlands and MIAMI, Aug. 26, 2026 (GLOBE NEWSWIRE) — NewAmsterdam Pharma Company N.V.…
#Europe #EU #biopharmaceuticalcompany #Company #European #EuropeanSocietyofCardiology #oralpresentation #PhaseIIITrials #posterpresentation #SessionNumber #theCompany
https://www.europesays.com/europe/124484/

Greenwich LifeSciences Extends Lock-up of Directors and

STAFFORD, Texas, Aug. 10, 2026 (GLOBE NEWSWIRE) — Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical…
#London #Britain #UnitedKingdom #UK #GB #England #Headlines #News #Europe #EU #Greenwich #biopharmaceuticalcompany #clinical-stage #FLAMINGO-01 #GreenwichLifeSciences #Inc. #Nasdaq:GLSI #PhaseIIIclinicaltrial
https://www.europesays.com/gbr/london/10636/

https://www.europesays.com/dk/142320/ Pfizer’s Next Weight-Loss Weapon: How Berobenatide Stacks Up Against Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound #AntiObesity #BiopharmaceuticalCompany #EliLilly #NovoNordisk #Pfizer #Phase3Studies #TheMotleyFool #WeightLoss #WeightManagement

https://www.europesays.com/uk/1116782/ FDA Approves Mannkind’s At-Home Treatment Option for Heart Failure or Kidney Disease #BiopharmaceuticalCompany #ChronicKidneyDisease #FoodAndDrugAdministration #FuroscixReadyFlow #Health #HeartFailure #MannKindCorporation #Medication #UK #UnitedKingdom

FDA Approves Mannkind’s At-Home Treatment Option for Heart Failure or Kidney Disease

Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below. Mannkind…
#NewsBeep #News #US #USA #UnitedStates #UnitedStatesOfAmerica #Medication #biopharmaceuticalcompany #chronickidneydisease #foodanddrugadministration #FuroscixReadyFlow #Health #heartfailure #MannKindCorporation
https://www.newsbeep.com/us/789781/

FDA Approves Mannkind’s At-Home Treatment Option for Heart Failure or Kidney Disease

Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below. Mannkind…
#NewsBeep #News #Medication #biopharmaceuticalcompany #CA #Canada #ChronicKidneyDisease #foodanddrugadministration #FuroscixReadyFlow #Health #Heartfailure #MannKindCorporation
https://www.newsbeep.com/ca/832005/

FDA Approves Mannkind’s At-Home Treatment Option for Heart Failure or Kidney Disease

Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below. Mannkind…
#NewsBeep #News #Medication #AU #Australia #biopharmaceuticalcompany #ChronicKidneyDisease #foodanddrugadministration #FuroscixReadyFlow #Health #Heartfailure #MannKindCorporation
https://www.newsbeep.com/au/829597/

FDA Approves Mannkind’s At-Home Treatment Option for Heart Failure or Kidney Disease

Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below. Mannkind…
#NewsBeep #News #Medication #biopharmaceuticalcompany #chronickidneydisease #foodanddrugadministration #FuroscixReadyFlow #Health #heartfailure #MannKindCorporation #UK #UnitedKingdom
https://www.newsbeep.com/uk/715852/

https://www.europesays.com/ie/608509/ FDA Approves Mannkind’s At-Home Treatment Option for Heart Failure or Kidney Disease #BiopharmaceuticalCompany #ChronicKidneyDisease #Éire #FoodAndDrugAdministration #FuroscixReadyFlow #Health #HeartFailure #IE #Ireland #MannKindCorporation #Medication

European Patent Office Confirms Patent Protection for SOT201, SOTIO’s Clinical-Stage Immunocytokine Showing Promising Anti-Tumor Activity

SOTIO Biotech B.V. PRAGUE and BASEL, Switzerland and BOSTON, July 21, 2026 (GLOBE NEWSWIRE) — SOTIO Biotech, a…
#Europe #EU #biopharmaceuticalcompany #BoardsofAppeal #European #EuropeanPatentOffice #InstitutNationaldelaSanté #intellectualproperty #Phase1clinicaltrial #PPFGroup #SOTIO
https://www.europesays.com/europe/99518/

Eikon Therapeutics Announces Seven Abstracts Accepted for Presentation at the 2026 European Society of Medical Oncology (ESMO) Congress

Eikon Therapeutics, Inc. Presentations to cover updates across Eikon’s clinical pipeline including:  Updated data from TeLuRide-005, an ongoing…
#Europe #EU #biopharmaceuticalcompany #Eikon #EikonTherapeutics #European #Forward-LookingStatements
https://www.europesays.com/europe/98372/

https://www.europesays.com/news/53236/ Eli Lilly to buy psychedelic drugmaker AtaiBeckley for up to $3.8 billion in bet on depression therapy #AtaiBeckley #BiopharmaceuticalCompany #EliLilly #Headlines #News #TopStories

https://www.europesays.com/dk/128427/ Vivani Medical Enters into Agreement with Novo Nordisk to Evaluate NPM-139, a Miniature, Ultra Long-Acting Semaglutide Implant for Chronic Weight Management #BiopharmaceuticalCompany #Company #Development #ForwardLookingStatements #Inc #NovoNordisk #VivaniMedical #VivaniPresident

Greenwich LifeSciences Announces European Approval for Use

STAFFORD, Texas, July 09, 2026 (GLOBE NEWSWIRE) — Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical…
#Europe #EU #biopharmaceuticalcompany #commercialfacility #European #EuropeanMedicinesAgency #FLAMINGO-01 #GreenwichLifeSciences #Inc. #Nasdaq:GLSI #PhaseIIbclinicaltrial
https://www.europesays.com/europe/90158/

Bristol Myers Squibb vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026?

Choosing between established healthcare giants often comes down to balancing income needs against growth potential. Both Bristol Myers…
#NewsBeep #News #Healthcare #biopharmaceuticalcompany #BristolMyersSquibb #CA #Canada #freecashflow #Health #Johnson&Johnson #shareholderequity
https://www.newsbeep.com/ca/767626/

https://www.europesays.com/ie/558692/ Bristol Myers Squibb vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026? #BiopharmaceuticalCompany #BristolMyersSquibb #Éire #FreeCashFlow #Health #HealthCare #Healthcare #IE #Ireland #Johnson&Johnson #ShareholderEquity

European Growth Companies With High Insider Ownership June 2026

As European markets navigate a period of uncertainty, marked by mixed economic signals and geopolitical developments, investors are…
#Europe #EU #biopharmaceuticalcompany #EarningsGrowth #European #Europeanmarkets #growthcompanies #hematologydisorders #insiderownership #revenuegrowth
https://www.europesays.com/europe/65513/

https://www.europesays.com/britain/59780/ GSK Signs $10.6 Billion Deal to Acquire US Biopharma Nuvalent in Oncology Push #acquisition #AggregateInvestment #BiopharmaceuticalCompany #GSK #GSKShares #Nuvalent #PharmaceuticalGiant

High Growth Tech Stocks in Europe with Promising Potential

The European market has shown resilience with the pan-European STOXX Europe 600 Index edging up slightly, as investors…
#Europe #EU #biopharmaceuticalcompany #EarningsGrowth #Europeanmarket #innovationcapabilities #PharmingGroup #revenuegrowth
https://www.europesays.com/europe/61048/

European Market Gems: S.C. Comcm Leads 3 Promising Penny Stocks

As European markets navigate the complexities of geopolitical developments and economic shifts, investors are increasingly attentive to opportunities…
#Europe #EU #AelisFarma #biopharmaceuticalcompany #European #Europeanmarkets #marketcapitalization #Pennystocks #revenuestreams #SimplyWallStFinancialHealthRating #StFinancialHealthRating
https://www.europesays.com/europe/60494/